文献速递乳腺癌

HER2阳性乳腺癌辅助曲妥珠单抗序贯与同期给药结局相当:SIGNAL/PHARE前瞻性队列结果

Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort.
PubMed 文献 · Eur J Cancer · 2017-06-16

该研究基于SIGNAL/PHARE前瞻性队列,纳入11728例辅助治疗的乳腺癌患者,其中5502例HER2阳性,比较序贯与同期给予曲妥珠单抗联合化疗的结局。中位随访58个月,经倾向性评分调整后,两组总生存(HR=1.01;95%CI:0.86-1.19)和无病生存(HR=1.08;95%CI:0.96-1.21)相似,提示序贯给药可能不劣于同期给药。

要点

  • HER2阳性乳腺癌辅助治疗中,序贯与同期曲妥珠单抗的总生存和无病生存无显著差异。
  • 调整后总生存HR=1.01(95%CI:0.86-1.19),无病生存HR=1.08(95%CI:0.96-1.21)。
  • 中位随访58个月,序贯给药可能不劣于同期给药。

核心结论

  • 在辅助治疗中,化疗完成后序贯给予曲妥珠单抗可能不劣于曲妥珠单抗与紫杉类化疗同期给药。

研究设计与样本

  • 研究人群来自PHARE随机III期临床试验(NCT00381901)和SIGNAL前瞻性研究(RECF1098)的合并队列,共纳入11728例辅助治疗的乳腺癌患者,其中5502例为HER2阳性。
  • 中位随访58个月,治疗方式由医生选择,采用倾向性评分方法进行调整比较。
  • 总生存和无病生存采用Kaplan-Meier法估计,组间比较基于log-rank检验。

主要发现

  • HER2阳性患者中,34.5%(1897/5502)接受序贯给药,65.5%(3605/5502)接受同期给药。
  • 调整后总生存相似(HR=1.01;95%CI:0.86-1.19)。
  • 调整后无病生存相似(HR=1.08;95%CI:0.96-1.21)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Adjuvant clinical trials in early human epidermal growth factor receptor 2 (HER2)-positive breast cancer have assessed either sequential or concomitant incorporation of trastuzumab with chemotherapy; only the North Central Cancer Treatment Group (NCCTG)-N9831 trial prospectively compared both modalities. In routine trastuzumab has been incorporated into a concurrent regimen with taxane chemotherapy instead of sequential modality on the basis of a positive risk-benefit ratio. This present study assessed sequential versus concomitant administration of adjuvant trastuzumab. METHODS: A population combining patients from Protocol for Herceptin® as Adjuvant therapy with Reduced Exposure (PHARE) a randomised phase III clinical trial (NCT00381901) and SIGNAL (RECF1098) a prospective study specifically designed for Genome-wide Association Studies (GWAS) analyses was studied. In this cohort with 58 months of median follow-up, the comparison in the HER2-positive group of adjuvant trastuzumab and chemotherapy modalities was based on a propensity score methodology. Treatment modalities were based on physician's choice and comparisons adjustment were made by a propensity score methodology. Overall Survival (OS) and Disease-Free Survival (DFS) were estimated using the Kaplan-Meier method, and comparisons between groups were based on the log rank test. RESULTS: The SIGNAL/PHARE cohort included 11,728 breast cancer cases treated in adjuvant setting; some 5502 of them with HER2-positive tumour: 34.5% (1897/5502) were treated by sequential and 65.5% (3605/5502) by concomitant modality of administration for taxane-chemotherapy and trastuzumab. The adjusted comparison found similar OS (HR = 1.01; 95% CI: 0.86-1.19) and similar DFS (HR = 1.08; 95% CI: 0.96-1.21). CONCLUSION: These results suggest that the sequential administration of trastuzumab given after the completion of adjuvant chemotherapy might be as valid as the concomitant administration of trastuzumab and taxane chemotherapy in the adjuvant setting.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Pivot X, Fumoleau P, Pierga JY, et al. Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort. Eur J Cancer. 2017. PMID: 28624696. doi:10.1016/j.ejca.2017.05.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。